Id |
Subject |
Object |
Predicate |
Lexical cue |
T725 |
0-15 |
Sentence |
denotes |
Antiviral Drugs |
T726 |
16-223 |
Sentence |
denotes |
Several classes of routinely used antiviral drugs, like oseltamivir (neuraminidase inhibitor), acyclovir, ganciclovir, and ribavirin, do not have any effect on COVID-19 and, hence, are not recommended (187). |
T727 |
224-421 |
Sentence |
denotes |
Oseltamivir, a neuraminidase inhibitor, has been explored in Chinese hospitals for treating suspected COVID-19 cases, although proven efficacy against SARS-CoV-2 is still lacking for this drug (7). |
T728 |
422-738 |
Sentence |
denotes |
The in vitro antiviral potential of FAD-approved drugs, viz., ribavirin, penciclovir, nitazoxanide, nafamostat, and chloroquine, tested in comparison to remdesivir and favipiravir (broad-spectrum antiviral drugs) revealed remdesivir and chloroquine to be highly effective against SARS-CoV-2 infection in vitro (194). |
T729 |
739-956 |
Sentence |
denotes |
Ribavirin, penciclovir, and favipiravir might not possess noteworthy in vivo antiviral actions for SARS-CoV-2, since higher concentrations of these nucleoside analogs are needed in vitro to lessen the viral infection. |
T730 |
957-1131 |
Sentence |
denotes |
Both remdesivir and chloroquine are being used in humans to treat other diseases, and such safer drugs can be explored for assessing their effectiveness in COVID-19 patients. |
T731 |
1132-1291 |
Sentence |
denotes |
Several therapeutic agents, such as lopinavir/ritonavir, chloroquine, and hydroxychloroquine, have been proposed for the clinical management of COVID-19 (299). |
T732 |
1292-1624 |
Sentence |
denotes |
A molecular docking study, conducted in the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 using different commercially available antipolymerase drugs, identified that drugs such as ribavirin, remdesivir, galidesivir, tenofovir, and sofosbuvir bind RdRp tightly, indicating their vast potential to be used against COVID-19 (305). |
T733 |
1625-1853 |
Sentence |
denotes |
A broad-spectrum antiviral drug that was developed in the United States, tilorone dihydrochloride (tilorone), was previously found to possess potent antiviral activity against MERS, Marburg, Ebola, and Chikungunya viruses (306). |
T734 |
1854-1938 |
Sentence |
denotes |
Even though it had broad-spectrum activity, it was neglected for an extended period. |
T735 |
1939-2018 |
Sentence |
denotes |
Tilorone is another antiviral drug that might have activity against SARS-CoV-2. |
T736 |
2019-2256 |
Sentence |
denotes |
Remdesivir, a novel nucleotide analog prodrug, was developed for treating Ebola virus disease (EVD), and it was also found to inhibit the replication of SARS-CoV and MERS-CoV in primary human airway epithelial cell culture systems (195). |
T737 |
2257-2368 |
Sentence |
denotes |
Recently, in vitro study has proven that remdesivir has better antiviral activity than lopinavir and ritonavir. |
T738 |
2369-2650 |
Sentence |
denotes |
Further, in vivo studies conducted in mice also identified that treatment with remdesivir improved pulmonary function and reduced viral loads and lung pathology both in prophylactic and therapeutic regimens compared to lopinavir/ritonavir-IFN-γ treatment in MERS-CoV infection (8). |
T739 |
2651-2796 |
Sentence |
denotes |
Remdesivir also inhibits a diverse range of coronaviruses, including circulating human CoV, zoonotic bat CoV, and prepandemic zoonotic CoV (195). |
T740 |
2797-2904 |
Sentence |
denotes |
Remdesivir is also considered the only therapeutic drug that significantly reduces pulmonary pathology (8). |
T741 |
2905-3043 |
Sentence |
denotes |
All these findings indicate that remdesivir has to be further evaluated for its efficacy in the treatment of COVID-19 infection in humans. |
T742 |
3044-3179 |
Sentence |
denotes |
The broad-spectrum activity exhibited by remdesivir will help control the spread of disease in the event of a new coronavirus outbreak. |
T743 |
3180-3347 |
Sentence |
denotes |
Chloroquine is an antimalarial drug known to possess antiviral activity due to its ability to block virus-cell fusion by raising the endosomal pH necessary for fusion. |
T744 |
3348-3493 |
Sentence |
denotes |
It also interferes with virus-receptor binding by interfering with the terminal glycosylation of SARS-CoV cellular receptors, such as ACE2 (196). |
T745 |
3494-3701 |
Sentence |
denotes |
In a recent multicenter clinical trial that was conducted in China, chloroquine phosphate was found to exhibit both efficacy and safety in the therapeutic management of SARS-CoV-2-associated pneumonia (197). |
T746 |
3702-3835 |
Sentence |
denotes |
This drug is already included in the treatment guidelines issued by the National Health Commission of the People’s Republic of China. |
T747 |
3836-3946 |
Sentence |
denotes |
The preliminary clinical trials using hydroxychloroquine, another aminoquinoline drug, gave promising results. |
T748 |
3947-4062 |
Sentence |
denotes |
The COVID-19 patients received 600 mg of hydroxychloroquine daily along with azithromycin as a single-arm protocol. |
T749 |
4063-4146 |
Sentence |
denotes |
This protocol was found to be associated with a noteworthy reduction in viral load. |
T750 |
4147-4303 |
Sentence |
denotes |
Finally, it resulted in a complete cure (271); however, the study comprised a small population and, hence, the possibility of misinterpretation could arise. |
T751 |
4304-4512 |
Sentence |
denotes |
However, in another case study, the authors raised concerns over the efficacy of hydroxychloroquine-azithromycin in the treatment of COVID-19 patients, since no observable effect was seen when they were used. |
T752 |
4513-4608 |
Sentence |
denotes |
In some cases, the treatment was discontinued due to the prolongation of the QT interval (307). |
T753 |
4609-4694 |
Sentence |
denotes |
Hence, further randomized clinical trials are required before concluding this matter. |
T754 |
4695-4807 |
Sentence |
denotes |
Recently, another FDA-approved drug, ivermectin, was reported to inhibit the in vitro replication of SARS-CoV-2. |
T755 |
4808-4975 |
Sentence |
denotes |
The findings from this study indicate that a single treatment of this drug was able to induce an ∼5,000-fold reduction in the viral RNA at 48 h in cell culture. (308). |
T756 |
4976-5091 |
Sentence |
denotes |
One of the main disadvantages that limit the clinical utility of ivermectin is its potential to cause cytotoxicity. |
T757 |
5092-5284 |
Sentence |
denotes |
However, altering the vehicles used in the formulations, the pharmacokinetic properties can be modified, thereby having significant control over the systemic concentration of ivermectin (338). |
T758 |
5285-5619 |
Sentence |
denotes |
Based on the pharmacokinetic simulation, it was also found that ivermectin may have limited therapeutic utility in managing COVID-19, since the inhibitory concentration that has to be achieved for effective anti-SARS-CoV-2 activity is far higher than the maximum plasma concentration achieved by administering the approved dose (340). |
T759 |
5620-5761 |
Sentence |
denotes |
However, ivermectin, being a host-directed agent, exhibits antiviral activity by targeting a critical cellular process of the mammalian cell. |
T760 |
5762-5872 |
Sentence |
denotes |
Therefore, the administration of ivermectin, even at lower doses, will reduce the viral load at a minor level. |
T761 |
5873-6017 |
Sentence |
denotes |
This slight decrease will provide a great advantage to the immune system for mounting a large-scale antiviral response against SARS-CoV-2 (341). |
T762 |
6018-6235 |
Sentence |
denotes |
Further, a combination of ivermectin and hydroxychloroquine might have a synergistic effect, since ivermectin reduces viral replication, while hydroxychloroquine inhibits the entry of the virus in the host cell (339). |
T763 |
6236-6396 |
Sentence |
denotes |
Further, in vivo studies and randomized clinical control trials are required to understand the mechanism as well as the clinical utility of this promising drug. |
T764 |
6397-6482 |
Sentence |
denotes |
Nafamostat is a potent inhibitor of MERS-CoV that acts by preventing membrane fusion. |
T765 |
6483-6579 |
Sentence |
denotes |
Nevertheless, it does not have any sort of inhibitory action against SARS-CoV-2 infection (194). |
T766 |
6580-6785 |
Sentence |
denotes |
Recently, several newly synthesized halogenated triazole compounds were evaluated, using fluorescence resonance energy transfer (FRET)-based helicase assays, for their ability to inhibit helicase activity. |
T767 |
6786-7028 |
Sentence |
denotes |
Among the evaluated compounds, 4-(cyclopent-1-en-3-ylamino)-5-[2-(4-iodophenyl)hydrazinyl]-4H-1,2,4-triazole-3-thiol and 4-(cyclopent-1-en-3-ylamino)-5-[2-(4-chlorophenyl)hydrazinyl]-4H-1,2,4-triazole-3-thiol were found to be the most potent. |
T768 |
7029-7178 |
Sentence |
denotes |
These compounds were used for in silico studies, and molecular docking was accomplished into the active binding site of MERS-CoV helicase nsp13 (21). |
T769 |
7179-7325 |
Sentence |
denotes |
Further studies are required for evaluating the therapeutic potential of these newly identified compounds in the management of COVID-19 infection. |